IVD Market Trends Report, March 2023

Table of Contents

Chapter 1: Worldwide IVD Market – March 2023 Update

IVD Market Demand and Growth

• Figure 1-1: Quarter-by-Quarter Segment Performance Commentary, 2022
• Table 1-1: Global In Vitro Diagnostic Sales by Product Market, 2022 ($ million) (Clinical Chemistry; Immunoassays: Infectious disease, Other immunos, Blood bank screening, Drugs of Abuse, Diabetes HbA1c – lab; Hematology – Core Lab; Microbiology (ID/AST); Microbiology (molecular); Microbiology – Mass Spectrometry; Coagulation (PT/INR); Coagulation, molecular; Histology/cytology; HPV, molecular; Nucleic acid assays; Blood grouping/typing; Blood bank molecular – NAT Screens; Circulating tumor cells; POC, OTC diabetes; POC, OTC other; POC, professional/hospital; Mass Spectrometry; Other IVD)
• Figure 1-2: IVD Segment Performance (Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, POC, Other), Q1 2022 – Q4 2022 ($MN)
• Figure 1-3: IVD Segment Performance (Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, POC, Other), Total Market Value, 2022 ($MN)

COVID-19 Diagnostic Markets

• Table 1-2: COVID-19 Product Sales — Immunoassay (Antigen, Serology), Molecular, Rapid — 2022  ($ millions)

Effect of COVID-19 on Market Segments

• Table 1-3: IVD Market excluding and with COVID-19, 2022
• Figure 1-4: IVD Market Distribution by Segment (COVID-19 Assays and Instruments, IVD Market excluding COVID-19 Assays and Instruments), 2022
• Figure 1-5: IVD Market by COVID-19 and non-COVID markets, Quarterly Performance, 2022
• Table 1-4: Global In Vitro Diagnostic Market – YoY Growth 2021-2022
• Figure 1-6: Global In Vitro Diagnostic Market – YoY Growth, by Segment (Blood Bank Molecular – NAT Screens, Blood Grouping/Typing, Clinical Chemistry, Coagulation (PT/INR), D-Dimer, Diabetes HbA1c lab, Drugs of Abuse, Hematology – Core Lab, Histology/Cytology, Immuno – Blood Bank Screening, Immuno – Infectious Disease, Microbiology (ID/AST), Microbiology (Molecular), Nucleic Acid Assays/genetic Tests, Other Immunos, POC – OTC Diabetes, POC – OTC Other, POC – Professional/Hospital), 2021-2022

 

Chapter 2: Product Trends and New Developments

Selected New – Q4 2022 and Q1 2023 – Core IVD Product Launches, Developments and Trends

Immunoassay

Molecular

Personalized Medicine

POC

Sequencing

Selected COVID-19 Developments – Q4 2022 – Q1 2023

• Figure 2-1: COVID-19 Test Market by Type, Q1-Q4 2022 – COVID-19 Testing Wanes

Antigen/Antibody

Molecular

 

Chapter 3: Top IVD Market Participant Results

Selected Competitive Leader Updates

• Figure 3-1: IVD Segment Growth by Leading Competitors (Abbott Diagnostics, Becton Dickinson, bioMérieux, Danaher, Hologic, QuidelOrtho, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific), Change in Sales, 2021-2022
• Figure 3-2: Changes in Market Distribution for IVD Sales, 2019-2022 – Roche and Abbott Battle for #1 Spot
• Figure 3-3: Comparison of Total Diagnostic Sales for Abbott vs Roche 2020-2022 (in millions $)

2022 M&A Activity

• Table 3-1: IVD-Relevant M&A Activity, 2022
• Figure 3-4: Count of IVD Industry M&A Deals by Month, Full Year 2022 and Jan-Feb 2023

Abbott Laboratories

• Table 3-2: Abbott Corporate Summary
• Figure 3-5: Abbott Diagnostics Revenue by Segment (Core Laboratory, Molecular, Point-of-Care, Rapid Diagnostics, COVID-19), Full Year 2021 and 2022 $M

Becton Dickinson and Co

• Table 3-3: Becton Dickinson Corporate Summary
• Figure 3-6: BD Life Sciences, Revenues by Business FY End September 30, 2021, and 2022 $M

bioMérieux SA

• Table 3-4: bioMérieux Corporate Summary
• Figure 3-7: bioMérieux Clinical Applications Segment, Full Year Results, 2021, 2022 € MN

Danaher Corporation

• Table 3-5: Danaher Corporation Summary
• Figure 3-8: Danaher Diagnostic Segment Performance, Full Year Results, 2021 ,2022 $M

Hologic, Inc.

• Table 3-6: Hologic Corporate Summary
• Figure 3-9: Hologic Diagnostic Segment Performance, Full Year Results, FY 2021 and FY 2022, $M

QuidelOrtho Corporation

• Table 3-7: QuidelOrtho Corporate Summary
• Figure 3-10: QuidelOrtho, Full Year Results, by Segment (Immunoassay/Clinical Lab, Molecular Diagnostics, Point-of-Care, Transfusion Medicine) $M (2021, 2022)

Roche Diagnostic

• Table 3-8: Roche Diagnostic Corporate Summary
• Figure 3-11: Roche Diagnostics Revenue by Product Group (Core Lab, Diabetes Care, Molecular, Pathology Lab, Point-of-Care), Full Year Results 2021, 2022, CHF MN

Siemens Healthineers

• Table 3-9: Siemens Healthineers Corporate Summary
• Figure 3-12: Siemens Diagnostics Revenue, FY 2021 and FY 2022, € MN

Sysmex Corporation

• Table 3-10:  Sysmex Corporate Summary
• Figure 3-13: Sysmex Revenue by Product Segment (Clinical Chemistry, FCM, Hematology, Hemostasis, Immunochemistry, Urinalysis, Others), FY 2021, 2022 and 2023, JPY MN

Thermo Fisher Scientific

• Table 3-11: Thermo Fisher Scientific Corporate Summary
• Figure 3-14: Thermo Fisher Scientific COVID-19 Response Revenue, 2021 and 2022, by Quarter $B

 

Chapter 4: New Opportunities

Artificial Intelligence Future Trends

At-Home Testing

Multiplex Testing

Telehealth